OBJECTIVES: The objective of the study was to assess the cost of using different blood pumps for short-term ventricular assist device (VAD) and extracorporeal life support (ECLS) systems for cardiac and cardiorespiratory failure in the UK.
INTRODUCTION
Mechanical circulatory support using ventricular assist device (VAD) or extracorporeal life support (ECLS) is a well-established treatment for critically ill patients with cardiac and cardiorespiratory failure [1] [2] [3] [4] . Long-term support may be used as a bridge to transplant or as a destination therapy [5, 6] . Temporary support for patients with acute cardiac failure is often required to provide time to determine further treatment strategy (bridge to long-term support or transplant) or to support patient until recovery of the heart [1] .
There are several situations in which short-term VAD support may be required, including posttransplant graft failure, post-LVAD placement right ventricular failure, post-cardiac surgery cardiogenic shock ( post-cardiotomy) and acute cardiac deterioration in patients with established end-stage heart failure (ESHF), or due to acute cardiac failure (myocardial infarction, myocarditis, acute cardiomyopathy) [7] [8] [9] [10] [11] . In the UK, an audit of all adult heart transplant patients between 2003 and 2008 revealed that VAD support for acute cardiac allograft failure was required in 6.6% of 568 heart transplant patients [12] . A telephone survey of the chief perfusionists at the cardiac surgical units in the UK and Ireland between October 2007 and October 2008 revealed that VADs for post-cardiotomy cardiogenic shock were required in 0.24% of patients undergoing coronary artery bypass grafting and/or valve surgery [13] . A similar incidence (0.3%) of VAD support after cardiac surgery was reported in the USA, using records from the Society of Thoracic Surgeons' National Cardiac Database between 1995 and 2004 [14] . In general cardiac practice, mechanical circulatory support is rarely required, but is the only life-saving option available for patients with cardiogenic shock and its use is increasing due to the availability of such support in most cardiac care units.
VAD and ECLS are well-established techniques with numerous devices available for clinical use. The use of a specific device is determined by clinical considerations and preferences and by the availability of equipment in the cardiac unit. Direct comparison of different technologies is complicated because temporary VAD support is used rarely, and newer generation devices have replaced older ones in the last 8 years.
Both clinical outcomes and treatment costs are critical in the adoption and wider usage of mechanical circulatory support. Both VAD and ECLS services are expensive. Previous studies have calculated the cost of VAD and ECLS therapies. The cost of open implantation (excluding the cost of device) of a single VAD was £16 634, and for a BiVAD it was £20 834, while the average total 1-month implant cost was £84 518 in the evaluation of the VAD programme in the UK [15] . The total 6-month cost of respiratory ECMO support was £73 979 compared with £33 435 in the conventional management arm in the CESAR trial of ECMO support for severe respiratory failure in adults [16] , although ECMO support in this study was performed using a roller pump system and 2:1 staffing rather than with the more sophisticated and less staff intensive pumping systems being considered here.
To the best of our knowledge, no cost evaluation of short-term VADs and pumps for ECLS in cardiac and cardiorespiratory failure in the UK has been performed. As number of devices is available on the market, it is important to guide decision-making about optimal selection of heart pump with minimal impact on hospital's budget. The objective of this study was to compare the cost of VAD and ECLS support for cardiac and cardiorespiratory failure using the blood pumps currently available in the UK.
MATERIALS AND METHODS
We performed a cost-minimization analysis as a part of the dossier development for sponsor evidence submission for CentriMag® blood pump for the Medical Technologies Evaluation Programme (MTEP) in the National Institute for Health and Care Excellence (NICE) in the UK. We followed the NICE MTEP Methods Guide to develop the presented cost analysis [17] .
Cost model
The cost analysis is based on evaluation of the time required to provide circulatory support for different indications, and the ability of different blood pumps to provide support for the necessary time period. If a pump provides support for a shorter period than that required for the given indication, it needs to be replaced, thus increasing the total cost of treatment. The required duration of circulatory support was taken from clinical studies [18, 19] , and the maximum duration of support for each device was based on the manufacturers' recommendation. The total treatment cost was evaluated only for the period of mechanical circulatory support.
The selected approach for evaluation of the cost impact of technologies is aligned with the clinical pathway for short-term ventricular support in the UK. The cost of using comparative technologies (VAD and ECLS systems) was evaluated, and varied depending on the cost of the technology, the cost of device insertion/implantation and the cost of device replacement based on the claimed maximum time for device use. Owing to the absence of comparative resource utilization and safety data, the cost of routine staff use, medications and complications was not included in the analysis. These parameters are not expected to differ among treatments.
Clinical indications
The following patient groups were included in the cost analysis: adults and children with post-cardiac surgery cardiogenic shock, adults with postacute myocardial infarction cardiogenic shock and adults and children with deteriorating ESHF. Due to limited data, patients with acute myocarditis and post-partum cardiomyopathy were excluded from the analysis.
Patients with post-heart transplant heart failure or post-LVAD implantation right ventricular failure were not included in the model, since CentriMag® is an established modality for short-term ventricular support in these clinical situations in the UK [12] .
Technologies
The blood pumps were selected based on briefing notes produced by the NICE Medical Technologies Advisory Committee Team and knowledge about current blood pump utilization in the UK.
Three VADs were selected for comparison in adults and two for comparison in children (Table 1) . Pneumatic temporary VADs were not selected as comparators due to their limited usage in the UK (BVS 5000 and AB 5000, Abiomed Inc., Danvers, MA, USA), and because these devices are intended for longer term support (up to several months) (Excor Berlin Heart, Berlin Heart Mediprodukt GmbH, Berlin, Germany; and Thoratec PVAD, Thoratec Corp., Pleasanton, CA, USA). Also, pneumatic temporary VADs are not used interchangeably with short-term VADs in clinical practice. The Biomedicus pump is approved for support as a part of the ECLS circuit, although, in clinical practice, it may be used as a VAD without an oxygenator in an off-label fashion. Biomedicus pumps with a Carmeda surface were selected for comparison, since they provide longer support (up to 48 h) compared with standard Biomedicus pumps without a Carmeda surface (6 h support).
Four centrifugal ECLS systems were selected for comparison in adults. The Terumo centrifugal ECLS system (Terumo, Tokyo, Japan) was not selected because this device is rarely used in the UK. Two ECLS systems were selected for comparison in children.
Clinical inputs
Due to limited comparative effectiveness and safety data for different blood pumps, two clinical assumptions were required in the analysis model. First, all devices are assumed to be equally effective in terms of patient survival. Second, pumps are used for the maximum approved time, and subsequently replaced with the same pump. In the EU, all CE-marked medical devices are approved on the basis of the manufacturer's claims alongside supportive clinical and technical data that are submitted to Notified Bodies. The manufacturer makes recommendations about requirements for product usage based on this supportive clinical and technical data. For instance, it is essential for heart pumps to specify the maximum time of support, hence allowing the device to be used safely within given indications. Exceeding the recommended maximum time for support may lead to unexpected safety and efficacy issues. Recommended maximum time for support was taken from the manufacturer's instructions for use of the pumps (Table 1) .
Data regarding the average time on mechanical support were obtained by a systematic literature review of clinical studies of the CentriMag® blood pump (Borisenko et al., not published). The study by De Robertis et al. [18] was used to identify the average time of mechanical support for post-cardiac surgery cardiogenic shock (8.3 days) and ESHF (26.0 days). Data from the clinical study by John et al. [19] were used to determine average support in post-AMI cardiogenic shock (17.0 days).
Cost inputs
Only the cost of the device (including capital cost, maintenance and consumables), device placement and the frequency of replacing the device (if required) were included in the analysis.
Since data regarding resource utilization and the cost in VAD and ECLS settings are limited, the analysis included only the cost of items that may differ between groups. Costs of items that are not supposed to differ between groups (e.g. cost of ICU stay, routine care for patients on ECLS, cost of lighting, heating, buildings etc.) are not included in the analysis. Therefore, the total cost estimates for comparisons will be lower than in the real costs in clinical practice.
The cost of a VAD includes the list price of capital equipment (console), pump, cannulae, additional components (tubes, probes) and maintenance. The cost of the ECLS system includes the list price of capital equipment (console), a pump, oxygenator, cannulae, additional components (tubes, probes) and maintenance. Prices were obtained from UK medical device distribution company (Chalice Medical Ltd). Maintenance cost for CentriMag®/ PediVAS® console is estimated as 6% of original cost once in 2 years, or 3% per year, whereas the maintenance cost of other consoles is estimated as 10% of the initial cost per year, as specified by distributor. The cost of capital equipment per patient was determined by dividing the cost of the console by the lifespan of the device (conservatively assumed to be equal to 7 years) and then by the average annual usage. The average annual usage for all pumps (10 usages per year) was based on the expert opinion and reflects the need for urgent mechanical support in patients with cardiogenic shock in transplant centres. The maintenance cost per patient was determined by dividing the total maintenance cost by the number of years of device lifespan, and then again by the average annual usage. All prices are given excluding VAT. Total price (including capital equipment, maintenance cost and single-use elements) for single use within licenced duration of support was £3542 for CentriMag®, £3559 for PediVAS®, £1500 for BPX-80 and BP-50 with Carmeda, £7364 for Impella 5.0, £7836 for Cardiohelp® and £3664 for DP3.
Resource utilization data for open and percutaneous VAD implantation/placement, ECLS system placement and pump replacement were obtained from Wythenshawe hospital, Manchester, UK. A microcosting approach was used, as Healthcare Resource Group costs do not reflect differences in cost between technologies. Resource utilization data reflected care provision only in adult patients. The total time spent by the staff (excluding radiologists) during open and percutaneous VAD placement and ECLS placement was based on procedure time. Unit costs for staff were based on official published estimates (PSSRU [20] ). The cost of a procedure was calculated as the sum of the cost of staff, operating room overheads, consumables and blood components. All costs were presented in 2011/2012 values. Inflation adjustment was performed using the Hospital and Community Health Services Index [20] . Unit costs are presented in Table 2 .
Total cost of procedures, used in the cost analysis, is presented in the Table 3 .
Sensitivity analysis
To assess the robustness of our cost estimates, an extensive one-way sensitivity analysis was performed to assess the impact of varying the model parameters, while holding other variables fixed at base-case values. Cost drivers (variables with a major implication on cost) were identified and the results presented as a tornado diagram and in a table format.
The following approach was used to select appropriate ranges for the sensitivity analyses:
(i) The cost of technology ( pump, console, cannulas, oxygenator, other consumables) was varied by ±20%; (ii) Numbers for annual usage varied only towards a lower conservative limit of 5 usages per year, and an upper limit of 15 usages per year; (iii) Device lifetime varied between 7 and 13 years; (iv) The percentage of total cost for annual maintenance of CentriMag®/PediVAS® varied from base-case (lower limit was considered equal to base-case) to 10%. For other devices, a lower value of 3% was used (equal to CentriMag's base-case value), and a maximum value equal to base-case value was used (10%); (v) The maximum (recommended) time of device support varied only towards an upper limit of +200%, reflecting the potential off-label use of devices for longer time periods than those indicated in the instructions for use. The lower limit was equal to base-case value; (vi) Unit costs for staff, the operating theatre, cath lab consumables, overhead costs, diagnostic procedures and blood and its components varied by ±20%; (vii) The time required to perform implantation/placement of different devices and replace the pump varied in accordance with the expert opinion (Supplementary Table 1 ); (viii) Staff requirements for the performance of different procedures varied by adding one additional staff member by specialization and subtracting one staff member when more than two staff members of that specialization were involved. It was considered inappropriate to completely remove staff members from the sensitivity analysis, as base-case staff composition was considered the minimum required to perform procedures; (ix) Assumptions on variance of radiology/ECHO services (including radiologist utilization), pathology services and blood component requirements for procedures were made using a range between 100 and +100%; (x) Time of staff utilization for pump replacement varied only towards a maximum limit of +100%. 
Cost analysis
Hospital perspective was utilized for analysis. The costminimization analysis was performed using Microsoft Excel 2010 (Microsoft Corp., Redmond, Washington, DC, USA). Total cost per treatment was not obtained directly from hospital expense records, but was calculated as sum of cost of procedure to place/ replacement a device, cost of pump and consumables and cost of capital component (console and maintenance). A number of 'stress tests' were undertaken on the cost model to check its internal validity (Supplementary Table 2 ).
RESULTS
Base-case results (total cost per patient) for the VAD and ECLS indications are presented in Tables 4 and 5 
Sensitivity analysis
When compared with Cardiohelp®, the cost saved by CentriMag® was not altered by any change in the model variables (Fig. 1) . Using the CentriMag® led to greater savings with increasing duration of support (towards extreme values) [22, 23] . This was because multiple pump changes with the CentriMag® had a more favourable cost profile compared with Cardiohelp®. Additionally, 
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O. Borisenko et al. / Interactive CardioVascular and Thoracic Surgerythe ability to change individual circuit components, such as the oxygenator, provided an additional opportunity for cost savings with the CentriMag®. In the case of the CentriMag®, only the oxygenator needs to be changed while, in the Cardiohelp® system, individual components cannot be replaced without changing the whole circuit. In all other comparisons, cost savings of CentriMag® and PediVAS® was only altered by off-label use of other heart pumps and their use for an extremely short period of support (e.g. 1 day for ESHF).
DISCUSSION
To our knowledge, this study is the first attempt to evaluate the cost of different blood pumps for provision of short-term mechanical circulatory support for patients with cardiac and cardiorespiratory failure in the UK. Results of the analysis showed that CentriMag® pump in adults and PediVAS® pump in children can lead to savings to National Health Service (NHS) due to the lower cost of pumps and capital equipment, and the longer duration of support.
There are several potential areas of cost savings that are not reflected in the present cost model. Firstly, according to the clinical experience, CentriMag® demonstrated excellent stability and lower staff requirements compared with other devices. Since there were no data in the literature on staff requirements for different pumps, it was not possible to include this important cost component into the analysis. Secondly, only single ventricular VAD support was evaluated in the cost analysis. When providing biventricular support for patients, CentriMag® may generate additional resource savings.
The present cost analysis is relevant for both ECMO and transplant centres specialized in the provision of mechanical circula- tory support, and for tertiary cardiac centres that deal with cases of cardiogenic shock after cardiac surgery, acute myocardial infarction and ESHF. Two indications ( post-heart transplant graft rejection and post-LVAD placement right ventricular failure) were excluded from the cost analysis, as CentriMag® is an established 'gold standard' for these indications in the UK. Selection of heart pumps for analysis was determined by Briefing notes from NICE and expert opinion about usage of different devices in the UK, which may not reflect utilization of heart pumps in other geographies. For cost analysis in children, another commonly used pump (Excor Berlin Heart, Berlin Heart Mediprodukt GmbH, Berlin, Germany) may be used for shortterm support as well, although based on expert opinion, it is not a proper comparator to PediVAS® pump in real settings, as devices are aimed on different duration of support. Thus, in case series from Paediatric Intensive Care Unit at Freeman Hospital, Newcastle upon Tyne, UK, median duration of support with Excor Berlin Heart was 44 days (range, 7-150 days) in comparison with 10 days (range, 5-16 days) of support using PediVAS® [24] . The strength of this analysis is that it was performed using appropriate methodology in a situation where comparative effectiveness and safety data were absent. The cost analysis is based on the analysis of resources used and costs arising from usage of different pumps for short-term support (days and weeks) in patients with cardiac and cardiopulmonary insufficiency. Since all pumps have different properties (maximum time for use) and price, total cost of mechanical support differs between technologies.
The main limitation of the cost analysis is that it is not based on comparative effectiveness and safety data. A change of the pump or other component parts of the circuit may increase the risk of the treatment; however, this was not evaluated. However, taking into account the number of devices available on the market, their cost and the frequency of deployment, it is unlikely that a meaningful comparison will be done within a single unit. A comparison based on assumptions in a model is needed to identify cost differences that may exist between devices. While a number of heart pumps for short-term mechanical support are available, only few of them are developed to provide the required duration of support.
In critical care service provision, there are clinical and policy considerations when choosing devices for VAD and ECLS support. The choice of devices is determined by clinical preferences, which are driven by durability, safety, efficacy, performance, longevity of support and the need of additional expert staff to monitor the device. Another consideration includes method and ease of deployment, whether percutaneous or open. The choice is also determined by the equipment available in the hospital. A survey among perfusionists at cardiac surgical units around the UK and Ireland revealed that, approximately in half of the cases, a Biomedicus pump was used to support patients with post-cardiac surgery cardiogenic shock [13] . Although the device provides support of a limited duration, its use may be explained by the availability of the Biomedicus system for cardiopulmonary bypass. In the present analysis, CentriMag® may save £5014 per patient supported for post-cardiac surgery cardiogenic shock in comparison with BPX-80 pump.
Optimal selection of heart pump may generate substantial savings to heart care system even with restricted utilization of mechanical circulatory support. Thus, is results of present analysis would be extrapolated on support with ECLS of 100 adult patients, CentriMag® could save up to £429 400 compared with Cardiohelp® in all three evaluated clinical conditions. The NHS is currently under significant economic pressure. Our analysis shows that both the CentriMag® and PediVAS® blood pumps can lead to savings to the NHS, when used instead of other pumps for short-term VAD or ECLS support. Cost savings were determined by the low cost of devices and the sufficient licenced duration of mechanical support required to bridge patients to long-term mechanical support or recovery of the heart.
